CriticalAntiretroviral, HIV protease inhibitor×HMG-CoA reductase inhibitor (statin)
Updated · Methodology
Mechanism
Lovastatin metabolism depends heavily on CYP3A4, and atazanavir, which inhibits this enzyme, can raise lovastatin levels (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA). Atazanavir is an HIV protease inhibitor (EMA). The lovastatin SmPC lists HIV protease inhibitors among strong CYP3A4 inhibitors. They raise plasma inhibitory activity against HMG-CoA reductase, the enzyme that statins act on, and with it the risk of myopathy and rhabdomyolysis (lovastatin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Ritonavir inhibits CYP3A4 more strongly than atazanavir itself, and cobicistat is also a potent CYP3A inhibitor (atazanavir and atazanavir/cobicistat SmPCs, EMA). The documents give no figures for this pair.
Symptoms
Myopathy presents as muscle pain, tenderness or weakness with creatine kinase (CK) above 10 times the upper limit of normal (lovastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Myopathy sometimes progresses to rhabdomyolysis (muscle breakdown), with or without acute kidney failure due to myoglobin in the urine. Rarely, it is fatal (AEMPS). A warning sign is unexplained muscle pain, tenderness or weakness, especially with malaise or fever (lovastatin label, US Food and Drug Administration, FDA).
Management
The combination is contraindicated. Lovastatin is named in the contraindications of atazanavir regardless of the booster: in the European and US atazanavir documents and in the atazanavir/cobicistat SmPC (atazanavir and atazanavir/cobicistat summaries of product characteristics, SmPCs, European Medicines Agency, EMA; atazanavir label, US Food and Drug Administration, FDA). With ritonavir, the ritonavir SmPC also contraindicates lovastatin (ritonavir SmPC, EMA). The lovastatin documents also list HIV protease inhibitors among the contraindicated strong CYP3A4 inhibitors (lovastatin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; lovastatin FDA label). The Spanish lovastatin SmPC provides for pausing lovastatin during an unavoidable course of itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin only. HIV protease inhibitors are not on this list (AEMPS). For other statins, the atazanavir SmPC gives separate advice. It does not recommend atorvastatin, and if atorvastatin is strictly necessary, it advises the lowest possible dose with close safety monitoring. Use pravastatin and fluvastatin with caution (atazanavir SmPC, EMA). Explain to the patient the risk of myopathy and its signs: unexplained muscle pain, tenderness or weakness, especially with malaise or fever (lovastatin FDA label). If muscle pain, weakness or cramps appear, measure creatine kinase (CK). Stop lovastatin if CK is above 5 times the upper limit of normal without strenuous exercise or if myopathy is suspected. With severe muscle symptoms, consider stopping it even at a lower CK (lovastatin SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Lovastatina (nº registro 64438), sección 4.3 (2023)– AEMPS, CIMA, nº registro 64438, revisión 07/2023, sección 4.3
- FDA: Reyataz (atazanavir) prescribing information (2024)– DailyMed setid 165cff62-b284-4a27-a65d-9ec8a5bfcdd8, revisión 12/2024, secciones 4 y 7.3
- EMA: Ficha técnica: Ritonavir (EU/1/96/016), sección 4.3 (2026)– EMA, Norvir, ficha técnica en CIMA (nº registro 96016005), consultada 03.10.2026, secciones 4.3, 4.4 y 4.5
- FDA: Lovastatin Tablets USP (lovastatin) prescribing information (2026)– FDA, DailyMed setid df7ddf4f-d569-431e-81f1-9129d7043150 (Lupin Pharmaceuticals), revisión 05/2026 (versión 17), Clinical Pharmacology (tabla I), Contraindications, Warnings (Myopathy/Rhabdomyolysis) y Precautions
- EMA: Ficha técnica: Atazanavir, Reyataz (EU/1/03/267), sección 4.3 (2026)– EMA, Reyataz 300 mg cápsulas (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 03267008, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir/cobicistat, Evotaz (EU/1/15/1025), sección 4.3 (2026)– EMA, Evotaz 300 mg/150 mg comprimidos (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5